drugset / Trial / NCT01266590

A Study of LY2216684 and Digoxin in Healthy Subjects

NCT01266590

Phase 1 Completed 30 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with LY2216684. Information about any side effects that may occur will also be collected.

Timeline

Start
2010-12
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject edivoxetine Small molecule 18 mg Oral